Clinical Trial Detail

NCT ID NCT03831932
Title Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung Cancer
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors National Cancer Institute (NCI)

lung non-small cell carcinoma


Osimertinib + Telaglenastat

Age Groups: adult senior

No variant requirements are available.